hydralazine has been researched along with Diabetes Mellitus, Type 2 in 14 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To compare the effects of captopril with more conventional drugs on proteinuria and progression of renal disease, we conducted a prospective, 18-month study in 42 proteinuric (> 500 mg/day) NIDDM and, for comparison, in 31 nondiabetic patients with a variety of renal diseases (NDRD)." | 9.08 | Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. ( Campese, VM; Huang, TP; Liou, HH, 1995) |
| "Studies were performed to determine if early treatment with an angiotensin II (Ang II) receptor blocker (ARB), olmesartan, prevents the onset of microalbuminuria by attenuating glomerular podocyte injury in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with type 2 diabetes mellitus." | 7.78 | Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. ( Hara, T; Hayden, MR; Hitomi, H; Ichimura, A; Ito, S; Kaifu, K; Kawachi, H; Kiyomoto, H; Kobori, H; Kohno, M; Matsumoto, S; Nishijima, Y; Nishiyama, A; Ohsaki, H; Sofue, T; Sowers, JR; Urushihara, M; Whaley-Connell, A, 2012) |
| "Groups of db/db mice, with obesity and type 2 diabetes, were treated with aliskiren (3, 6, 12 and 25 mg kg(-1) day(-1)) or hydralazine (80 mg kg(-1) day(-1)) for 6 weeks, and the protective effects were extensively compared among groups." | 7.76 | Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y, 2010) |
| " To compare the effects of captopril with more conventional drugs on proteinuria and progression of renal disease, we conducted a prospective, 18-month study in 42 proteinuric (> 500 mg/day) NIDDM and, for comparison, in 31 nondiabetic patients with a variety of renal diseases (NDRD)." | 5.08 | Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. ( Campese, VM; Huang, TP; Liou, HH, 1995) |
| "This study aims to investigate the effect of the glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) liraglutide on retinal pathological findings as compared with insulin and hydralazine using an animal model of type 2 diabetes with obesity, hypertension, and hyperlipidemia." | 4.12 | Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats. ( Hoshino, S; Inoue, K; Kamijo-Ikemori, A; Kimura, K; Watanabe, M; Yamada, S, 2022) |
| "Studies were performed to determine if early treatment with an angiotensin II (Ang II) receptor blocker (ARB), olmesartan, prevents the onset of microalbuminuria by attenuating glomerular podocyte injury in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with type 2 diabetes mellitus." | 3.78 | Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats. ( Hara, T; Hayden, MR; Hitomi, H; Ichimura, A; Ito, S; Kaifu, K; Kawachi, H; Kiyomoto, H; Kobori, H; Kohno, M; Matsumoto, S; Nishijima, Y; Nishiyama, A; Ohsaki, H; Sofue, T; Sowers, JR; Urushihara, M; Whaley-Connell, A, 2012) |
| "Groups of db/db mice, with obesity and type 2 diabetes, were treated with aliskiren (3, 6, 12 and 25 mg kg(-1) day(-1)) or hydralazine (80 mg kg(-1) day(-1)) for 6 weeks, and the protective effects were extensively compared among groups." | 3.76 | Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. ( Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Liu, L; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y, 2010) |
| "We compared the effects of long-term treatment with the angiotensin-converting enzyme inhibitor perindopril and triple therapy (hydrochlorothiazide, reserpine, and hydralazine) on the metabolic and renal features in the SHR/N-corpulent (cp) rat, a genetic model of non-insulin-dependent diabetes mellitus and hypertension." | 3.69 | Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat. ( Abraham, AA; Michaelis, OE; Scalbert, E; Striffler, JS; Thibault, N; Velasquez, MT, 1997) |
| "Aliskiren is a direct renin inhibitor, which is expected to modify proangiogenic cells." | 1.43 | Aliskiren directly improves endothelial progenitor cell function from Type II diabetic patients. ( Chang, TT; Chen, JS; Chen, JW; Huang, PH; Lin, LY; Lin, SJ; Wu, TC, 2016) |
| "High body iron levels are found in type 2 diabetes mellitus (DM)." | 1.39 | Iron restriction prevents diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rat. ( Akahori, H; Masuyama, T; Matsumoto, M; Naito, Y; Sasaki, N; Tsujino, T, 2013) |
| "Prevention or retardation of diabetic nephropathy (DN) includes anti-hypertensive treatment with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) on the premises that these drugs have an added protective effect beyond their influence on BP." | 1.32 | Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. ( Inagi, R; Ishikawa, N; Koike, H; Kurokawa, K; Miyata, T; Mizuno, M; Nangaku, M; Sada, T; Ueda, Y; van Ypersele de Strihou, C; Yuzawa, H, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Yamada, S | 2 |
| Ogura, Y | 1 |
| Inoue, K | 2 |
| Tanabe, J | 1 |
| Sugaya, T | 1 |
| Ohata, K | 1 |
| Nagai, Y | 2 |
| Natsuki, Y | 1 |
| Hoshino, S | 2 |
| Watanabe, S | 1 |
| Ichikawa, D | 1 |
| Kimura, K | 2 |
| Shibagaki, Y | 1 |
| Kamijo-Ikemori, A | 2 |
| Watanabe, M | 1 |
| Kennedy, KN | 1 |
| Wang, YD | 1 |
| Matsumoto, M | 1 |
| Sasaki, N | 1 |
| Tsujino, T | 1 |
| Akahori, H | 1 |
| Naito, Y | 1 |
| Masuyama, T | 1 |
| Chang, TT | 1 |
| Wu, TC | 1 |
| Huang, PH | 1 |
| Chen, JS | 1 |
| Lin, LY | 1 |
| Lin, SJ | 1 |
| Chen, JW | 1 |
| Dong, YF | 1 |
| Liu, L | 1 |
| Kataoka, K | 1 |
| Nakamura, T | 1 |
| Fukuda, M | 1 |
| Tokutomi, Y | 1 |
| Nako, H | 1 |
| Ogawa, H | 1 |
| Kim-Mitsuyama, S | 1 |
| Zhang, MZ | 1 |
| Wang, S | 1 |
| Yang, S | 1 |
| Yang, H | 1 |
| Fan, X | 1 |
| Takahashi, T | 1 |
| Harris, RC | 1 |
| Sofue, T | 1 |
| Kiyomoto, H | 2 |
| Kobori, H | 2 |
| Urushihara, M | 1 |
| Nishijima, Y | 1 |
| Kaifu, K | 1 |
| Hara, T | 1 |
| Matsumoto, S | 1 |
| Ichimura, A | 1 |
| Ohsaki, H | 1 |
| Hitomi, H | 1 |
| Kawachi, H | 1 |
| Hayden, MR | 1 |
| Whaley-Connell, A | 1 |
| Sowers, JR | 1 |
| Ito, S | 1 |
| Kohno, M | 2 |
| Nishiyama, A | 2 |
| Nangaku, M | 1 |
| Miyata, T | 1 |
| Sada, T | 1 |
| Mizuno, M | 1 |
| Inagi, R | 1 |
| Ueda, Y | 1 |
| Ishikawa, N | 1 |
| Yuzawa, H | 1 |
| Koike, H | 1 |
| van Ypersele de Strihou, C | 1 |
| Kurokawa, K | 1 |
| Yao, L | 1 |
| Miyata, K | 1 |
| Ozawa, Y | 1 |
| Miyatake, A | 1 |
| Yukimura, T | 1 |
| Shokoji, T | 1 |
| Kimura, S | 1 |
| Abe, Y | 1 |
| Laustsen, G | 1 |
| Gilbert, M | 1 |
| Wimett, L | 1 |
| Liou, HH | 1 |
| Huang, TP | 1 |
| Campese, VM | 1 |
| Velasquez, MT | 1 |
| Striffler, JS | 1 |
| Abraham, AA | 1 |
| Michaelis, OE | 1 |
| Scalbert, E | 1 |
| Thibault, N | 1 |
| Shirasaki, Y | 1 |
| Masumura, H | 1 |
| Akashi, A | 1 |
1 trial available for hydralazine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases.
Topics: Adrenergic beta-Antagonists; Aged; Blood Pressure; Captopril; Diabetes Mellitus, Type 2; Diabetic Ne | 1995 |
13 other studies available for hydralazine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats.
Topics: Animals; Citrate (si)-Synthase; Comorbidity; Diabetes Mellitus, Type 2; Electron Transport Complex I | 2022 |
Glucagon-like peptide-1 receptor agonist, liraglutide, attenuated retinal thickening in spontaneously diabetic Torii fatty rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon-Like Peptide-1 R | 2022 |
A Curious Case of Transient Movement Disorder.
Topics: Antihypertensive Agents; Diabetes Mellitus, Type 2; Dyskinesias; Humans; Hydralazine; Hyperglycinemi | 2019 |
Iron restriction prevents diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rat.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic N | 2013 |
Aliskiren directly improves endothelial progenitor cell function from Type II diabetic patients.
Topics: Amides; Antihypertensive Agents; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation | 2016 |
Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes.
Topics: Amides; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Diabetes Mellitus, Experiment | 2010 |
Role of blood pressure and the renin-angiotensin system in development of diabetic nephropathy (DN) in eNOS-/- db/db mice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Captopri | 2012 |
Early treatment with olmesartan prevents juxtamedullary glomerular podocyte injury and the onset of microalbuminuria in type 2 diabetic rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Glucos | 2012 |
Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model.
Topics: Animals; Antihypertensive Agents; Arginine; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mel | 2003 |
Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2005 |
A look back at the most influential drug approvals of 2005.
Topics: Amyloid; Analgesics; Anticonvulsants; Antiparkinson Agents; Diabetes Mellitus, Type 2; Diphtheria-Te | 2006 |
Perindopril ameliorates glomerular and renal tubulointerstitial injury in the SHR/N-corpulent rat.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Diabetes Mellitus, Type | 1997 |
[Effect of an antihypertensive drug, budralazine, on glucose and lipid metabolism in diabetic SHR].
Topics: Animals; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, | 1986 |